{"abstract":"The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for pulmonary arterial hypertension. Patient-Focused Drug Development is part of FDA's performance commitments in the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patients' perspectives on the impact of pulmonary arterial hypertension on daily life, as well as their perspectives on the available therapies for pulmonary arterial hypertension.","action":"Notice of public meeting; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2014/02/07/2014-02629.html","cfr_references":[],"citation":"79 FR 7464","comment_url":null,"comments_close_on":"2014-07-14","correction_of":null,"corrections":[],"dates":"The public meeting will be held on May 13, 2014, from 1 p.m. to 5 p.m. Registration to attend the meeting must be received by April 30, 2014. See the SUPPLEMENTARY INFORMATION section for information on how to register for the meeting. Submit electronic or written comments by July 14, 2014.","disposition_notes":null,"docket_ids":["Docket No. FDA-2012-N-0967"],"dockets":[],"document_number":"2014-02629","effective_on":null,"end_page":7465,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2014/02/07/2014-02629.xml","html_url":"https://www.federalregister.gov/documents/2014/02/07/2014-02629/pulmonary-arterial-hypertension-public-meeting-on-patient-focused-drug-development","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2014-02629?publication_date=2014-02-07","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2014-02-07/2014-02629/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":483,"last_updated":"2026-07-27 06:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2014-02-07/pdf/2014-02629.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2014-02629.pdf?1391694592","publication_date":"2014-02-07","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2014/02/07/2014-02629.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2014-03-11T05:04:27Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":7464,"subtype":null,"title":"Pulmonary Arterial Hypertension Public Meeting on Patient-Focused Drug Development","toc_doc":"Pulmonary Arterial Hypertension; Patient-Focused Drug Development","toc_subject":"Meetings:","topics":[],"type":"Notice","volume":79}